^
    Back
    Association details:
    Biomarker:EGFR exon 20 mutation
    Cancer:Non Small Cell Lung Cancer
    Drug:Rybrevant (amivantamab-vmjw) (EGFR inhibitor, c-MET inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions

    Excerpt:
    ...- Participant must have histologically or cytologically confirmed, locally advanced or metastatic, nonsquamous non-small cell lung cancer (NSCLC) with documented primary epidermal growth factor receptor (EGFR) Exon 20ins activating mutation...
    Trial ID:
    PAPILLON
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer

    Excerpt:
    ...Cohort D: participants must have been previously diagnosed with an EGFR Exon 20 insertion and have...
    Trial ID:
    CHRYSALIS
    More C2 evidence
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Pre-Approval Access With Amivantamab (JNJ-61186372) in Participants With Metastatic Non-Small Cell Lung Cancer

    Excerpt:
    ...- Has histologically or cytologically confirmed unresectable or metastatic non-small cell lung (NSCLC) cancer with an epidermal growth factor receptor (EGFR) exon 20 insertion (Exon20ins),...
    Trial ID:
    NCT04599712
    Less C2 evidence
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ESMO 2023
    Title:

    1343P - Amivantimab as a salvage strategy post TKI (osimertinib/mobocertinib) in EGFRm NSCLC

    Published date:
    10/16/2023
    Excerpt:
    ...we present 13 patients who received amivantamab on top of their previous EGFR TKI for disease progression (Group A - common EGFRm+ & Group B - EGFR Exon20+)….The median progression-free survival was 4.7 months in both groups….Incorporating amivantamab to prior EGFR TKI treatment appears to be a feasible option, although osimertinib stands out as the most well-tolerated TKI with clinical efficacy.
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    IASLC-WCLC 2023
    Title:

    Adding Amivantamab as a Salvage Strategy Post EGFR TKI (Osimertinib/Mobocertinib) in EGFRm+ NSCLC

    Published date:
    08/08/2023
    Excerpt:
    8 had common EGFR mutations (Group A) and 5 EGFR exon 20 (Group B). All group A patients had osimertinib as last line before amivantimab while Group B, 3 patients received mobocertinib, 1 afatinib and 1 poziotinib. Amivantamab was administered on top of previous line in all patients .The objective response rate (ORR) was 75% in group A and 100% in group B.